Sensorion Provides Update on Hearing Loss Gene Therapies
The company highlights progress in its SENS-501 and GJB2-GT clinical programs, recent financing, and a leadership transition.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
